Thrombophilia and Stroke

REFERENCES

• Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost. 2000;83:1–2.
   PubMed Web of Science ®Google Scholar
• Dahlback R. Procoagulant and anticoagu-lant properties of coagulation factor V: factor V Leiden (APC resistance) causes hyperco-agulability by dual mechanisms. I Lab Clin Med. 1999;133:415–422.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarc-tion, stroke, and venous thrombosis in apparently healthy men. N Engl I Med. 1995;332:912–917.
   PubMed Web of Science ®Google Scholar
• Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin genera-tion in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995; 15:783–785.
   PubMed Web of Science ®Google Scholar
• Kontula K, Ylikorkala A, Miettinen H, et al. Arg506GIn factor V mutation (factor V Leiden) in patients with ischaemic cere-brovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558–560.
   PubMed Web of Science ®Google Scholar
• Lalouschek W, AuII S, Series W, Zeiler K. The prothrombin G2021 OA mutation and factor V Leiden mutation in patients with cerebrovascular disease. Blood. 1998;92: 704–705.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Strater R, Heinecke A, et al. Lippoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and meth-ylenetetrahydrofolate reductase are risk fac-tors of spontaenous ischemic stroke in child-hood. Blood. 1999;94:3678–3682.
   PubMed Web of Science ®Google Scholar
• Margaglione M, D'Andrea G, Giuliani N, et al. Inherited prothrombotic conditions and premature ischemic stroke. Arterioscler Thromb Vasc Biol. 1999;19:1751–1756.
   PubMed Web of Science ®Google Scholar
• Poort SR, Rosendaal FR, Reitsma PR, Bertina RM. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma pro-thrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703.
   PubMed Web of Science ®Google Scholar
• DeStefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G2021 OA mutant genotype is a risk factor for cerebrovascular ischemic dis-ease in young patients. Blood. 1998;91: 3562–3565.
   PubMed Web of Science ®Google Scholar
• Bloem BR, van Putten MJAM, vd Meer FJM, van Hilten JJ, Bertina RM. Superior sagittal sinus thrombosis in a patient heterozygous for the novel 20210A allele of the prothrom-bin gene. Thromb Haemost. 1998;79:235.
   PubMed Web of Science ®Google Scholar
• Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793–1797.
   PubMed Web of Science ®Google Scholar
• Mercier E, Quere I, Campello C, Mares P, Gris J-C. The 20210A allele of the prothrom-bin gene is frequent in young women with unexplained spinal cord infarction. Blood. 1998;92:1840–1841.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl I Med. 2001; 344:1527–1535.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C recep-tor plays an important role in protein C acti-vation in vivo. Blood. 2001;97:1685–1688.
   PubMed Web of Science ®Google Scholar
• Camerlingo M, Fnazzi G, Casto L, Laffranchi C, Barbui T, Mamoli A. Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults. Neurology. 1991;41: 1371–1373.
   PubMed Web of Science ®Google Scholar
• Strater R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study. Lancet. 2002;360: 1540–1545.
   PubMed Web of Science ®Google Scholar
• Taylor FB Jr. Protein S, C4b binding protein, and the hypercoagulable state. I Lab Clin Med. 1992;119:596–597.
   PubMedGoogle Scholar
• Schafer HP, von Felten A. Protein S deficien-cy in young patients with thrombotic cere-bral stroke. Schweiz Med Wochenschr. 1989;119:489–492.
   PubMedGoogle Scholar
• Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology. 1992;42:1029–1033.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Owen J, Mohr JP, Tatemichi TK, Grossman BA. Free protein S deficiency: a possible association with cerebrovascular occlusion. Stroke. 1989;20:1657–1661.
   PubMed Web of Science ®Google Scholar
• Sie P, Boneu B, Bierme R, Wiesel ML, Grunebaum L, Cazenave JP. Arterial throm-bosis and protein S deficiency. Thromb Haemost. 1989;62:1040.
   PubMed Web of Science ®Google Scholar
• Carr ME Jr, Zekert SL. Protein S and C4B-binding protein levels in young patients with stroke: implications for protein S regulation. Blood. 1991;87:213a.
   Google Scholar
• Broze GJ. Protein-Z and thrombosis. Lancet. 2001;357:900–901.
   PubMed Web of Science ®Google Scholar
• Vasse M, Guegan-Massardier E, Borg J-Y, Woimant F, Soria C. Frequency of protein Z deficiency in patients with ischemic stroke. Lancet. 2001;357:933–934.
   PubMed Web of Science ®Google Scholar
• Lopaciuk S, Bykowska K, Kwiecinski H, Czlonkowska A, Kuczynska-Zardzewialy A. Protein Z in young survivors of ischemic stroke [letter]. Thromb Haemost. 2002;88:436.
   PubMedGoogle Scholar
• Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990;10:672–679.
   PubMedGoogle Scholar
• Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98:2980–2987.
   PubMed Web of Science ®Google Scholar
• Simo JM, Joven J, Vilella E, et al. Impact of apolipoprotein (a) isoform size heterogene-ity on the lysine binding function of lipopro-tein (a) in early onset coronary artery dis-ease. Thromb Haemost. 2001;85:412–417.
   PubMed Web of Science ®Google Scholar
• Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl I Med. 1998;338: 1042–1050.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354: 407–413.
   PubMed Web of Science ®Google Scholar
• Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third national health and nutrition exam-ination survey (1991-1994): population ref-erence ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med. 1999;131:331–339.
   PubMed Web of Science ®Google Scholar
• D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1–11.
   PubMed Web of Science ®Google Scholar
• Perry Ii, Refsum H, Morris RW, Ebrahim SB, Ueland P, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398.
   PubMed Web of Science ®Google Scholar
• Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998;118: 1895–1901.
   Google Scholar
• Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly per-sons: the Framingham Study. Ann Intern Med. 1999;131:352–355.
   PubMed Web of Science ®Google Scholar
• Selhub J, Jacques PF, Bostom AG, et al. Association betweeen plasma homocysteine concentrations and extracrania I carotid-artery stenosis. N Engl I Med. 1995;332: 286–291.
   PubMed Web of Science ®Google Scholar
• Wenzler Em, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am I Ophthalmol. 1993;115:162–167.
   PubMed Web of Science ®Google Scholar
• Latronico N, Fassini P, Antonini B, Gasparotti R. A pain in the neck. Lancet. 2002;359:1206.
   PubMed Web of Science ®Google Scholar
• Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl I Med. 2002;346:476–483.
   PubMed Web of Science ®Google Scholar
• Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355:517–522.
   PubMed Web of Science ®Google Scholar
• Reuner KH, Rug A, Kaps M, Druschky KF, Patscheke H. The mutation C677T in the methylene tetrahydrofolate reductase gene and stroke. Thromb Haemost. 1998;79: 450–451.
   PubMed Web of Science ®Google Scholar
• Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol. 1998;18:1465–1469.
   PubMed Web of Science ®Google Scholar
• Demuth K, Moatti N, Hanon O, Benoit O, Safar M, Girerd X. Opposite effects of plas-ma homocysteine and the methylenete-trahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler Thromb Vasc Biol. 1998;18:1838–1843.
   PubMed Web of Science ®Google Scholar
• Rees DC, Liu YT, Cox MJ, Elliott P, Wainscoat JS. Factor V Leiden and thermo-labile methylenetetrahydrofolate reductase in extreme old age. Thromb Haemost. 1997;78:1357–1359.
   PubMed Web of Science ®Google Scholar
• Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl I Med. 2001;345:1593–1600.
   PubMed Web of Science ®Google Scholar
• Graham I. Homocysteine in health and disease. Ann Intern Med. 1999;131:387–388.
   PubMed Web of Science ®Google Scholar
• Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl I Med. 2002;346:752–763.
   PubMed Web of Science ®Google Scholar
• Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999;353:1348–1353.
   PubMed Web of Science ®Google Scholar
• Rich MW. Sneddon Syndrome and demen-tia. Mayo Clin Proc. 1999;74:1306.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagu-lants: an update. Thromb Haemost. 1995; 74:1185–1190.
   PubMed Web of Science ®Google Scholar
• Pratico D, Ferro D, Luliano L, et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood. 1999; 93:3401–3407.
   PubMed Web of Science ®Google Scholar
• Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 1998;79:276–281.
   PubMed Web of Science ®Google Scholar
• Field SL, Hogg PJ, Daly EB, et al. Lupus anti-coagulants form immune complexes with prothrombin and phospholipid that can aug-ment thrombin production in flow. Blood. 1999;94:3421–3431.
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The manage-ment of thrombosis in the antiphospholipid antibody syndrome. N Engl I Med. 1995; 332:993–997.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303–308.
   PubMed Web of Science ®Google Scholar
• Green D. Logical approach to the hyperco-agulable patient. In: Yao JST, Pearce WH, eds. Current Techniques in Vascular Surgery. New York: McGraw-Hill; 2001:431–442.
   Google Scholar
• Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet. 1994;344:452–456.
   PubMed Web of Science ®Google Scholar
• Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemor-rhagic stroke. Lancet. 1992;339:451–453.
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997–1002.
   PubMed Web of Science ®Google Scholar
• Angelini L, Ravelli A, Caporali R, Martini A. Antiphospholipid antibodies in children with idiopathic cerebral ischaemia. Lancet. 1994;344:1232.
   PubMed Web of Science ®Google Scholar